A Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 Diabetes

• Status: Completed
• Trial end date: 2006-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the efficacy and safety of adding Symlin to an established regimen of insulin glargine in subjects with type 2 diabetes who are not achieving glycemic targets.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Insulin; Insulin Glargine; Islet Amyloid Polypeptide; Pramlintide

Criteria

Inclusion Criteria:

• Has HbA1c >7.0% and <=10.5%

• Has a body mass index (BMI) >=25 kg/m2 and <=45 kg/m2

• Has received insulin glargine for 3 months prior to study start and has been on a stable dose for 1 month prior to study start

• If taking oral antidiabetic agents, has been on a stable dose for at least 2 months

Exclusion Criteria:

• Has been previously treated with Symlin/pramlintide (or has participated in a Symlin/pramlintide clinical study)

• Has received any investigational drug within 1 month of screening